Myomo Q2 revenue up 18% to $3.7M; record pipeline adds 52% YoY; net loss widens to $0.42/share

MYOMO, INC.

2022-Q2 EPS reported -$0.83 revenue$7,545,501

Revenue $3.7M (+18% YoY, +28% seq); product units 80, flat YoY; ASP up via direct billing (83% of revenue).
Record 420 new patient pipeline adds (+52% YoY); total pipeline 1,049; cost per addition halved from Q4 2021 to ~$2,470.
Gross margin 65.5%, down 550 bps YoY; net loss $2.9M ($0.42/shr) vs $2.6M ($0.46/shr) in Q2 2021.
Backlog 163 units (+2% YoY); operating loss $2.9M vs $2.6M; cash $10.2M; entered ELOC with Keystone Capital.
License payment from China JV delayed; expects sequential Q3 growth but lower YoY revenue; pipeline supports 12-mo outlook.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.